Merck said Thursday it will not seek regulatory approval for taranabant, an investigational medicine to treat obesity (similar to rimonabant).
The North Jersey pharmaceutical company has discontinued its clinical development program for the drug.
“Available phase-III data showed that both efficacy and adverse events were dose related, with greater efficacy and more adverse events in the higher doses,” said Dr. John Amatruda, senior vice president and research head of diabetes and obesity at Merck Research Laboratories.
More
No comments:
Post a Comment